GlycoMimetics, Inc. (NASDAQ:GLYC) traded at $3.74 at last check on Monday, Jun 29, making an upward move of 8.09% on its previous day’s price.
Looking at the stock we see that its previous close was $3.46 and the beta (5Y monthly) reads 2.5 with the day’s price range being $3.3500 – 3.9600. In terms of its 52-week price range, GLYC has a high of $13.44 and a low of $1.82. The company’s stock has gained about 32.16% over that past 30 days.
On the other hand, looking at the outlook for the GLYC stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of Hold.
Based on estimates by 5 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the GlycoMimetics, Inc. (GLYC) stock as a Hold, while 4 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the GLYC stock currently stands at 0, and the current price level is 24.71% off its SMA20 and 29.07% from its 50-day simple moving average. The RSI (14) is pointing at 70.23 while the volatility over the past week is 11.23% and jumps to 11.65% over the past one month. The beta value is 2.51, while the average true range (ATR) is currently pointing at 0.32. The average price target for the stock over the next 12 months is $9.75, with the estimates having a low of $4 and a high of $16. These price ends are 6.95% and +327.81% off the current price level respectively, although investors could be excited at the prospect of a +154.01% if the GLYC share price touches on the median price of $9.5.
Let’s briefly compare GlycoMimetics, (GLYC) stock to its peers. We find that today’s price change of +8.09% and -68.62% over the past 12 months for GLYC competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.51% in the latest trading session and is +16.29% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.25% today, and is +2.32% up over the past year, while Grifols S.A. (GRFS) is also up 8.09% yet its price remains in the red at -68.62% over the same period. Zoetis has a P/E ratio of 39.26 compared to GlycoMimetics,’s 0 and Takeda’s 22.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 2.32% and 1.47%, respectively, in early deals.
Coming back to GlycoMimetics, Inc. (NASDAQ:GLYC), we note that the average 3-month trading volume was 643.56 Million, while that of the preceding 10-day period stands at 1.45 Million. Current shares outstanding are 43.58 Million.
According to data from Thomson Reuters, insiders hold 2.24% of the company’s shares while institutions hold 94.72%. The data shows that short shares as of June 14, 2020, stood at 2.67 Million at a short ratio of 2.66. This represents a 6.12% Short interest in Shares outstanding on June 14, 2020. Shares short dropped in June from the previous month at 2.7 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -29.3% down in year-to-date price movement.